| |
Tuesday, December 3, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now.
|
|
Today’s Big NewsNov 22, 2024 |
|
Wednesday, December 4, 2024 | 11am ET / 8am PT Designing nanodevices that can change shape and function in response to molecular signals is a key objective in protein design, paving the way for the development of switchable nanomaterials, triggerable drug-delivery systems, and molecular motors. Join us for a deep dive into the recent progress in designing and characterizing a diverse range of switchable protein assemblies. Register now.
|
|
| By Darren Incorvaia Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to engage with us to explore a potential combination,” Halozyme president and CEO Helen Torley said in a Nov. 22 release. |
|
|
|
By Zoey Becker The pivot comes after the FDA issued a notice that the deficiencies in the company's approval bid for type 1 diabetes med Zynquista are too great to proceed for further discussion. |
By Conor Hale Version 2 of the TruSight Oncology 500 tissue research-use-only assay is currently under development, the company said, with a global release set for mid-2025. |
By Nick Paul Taylor A patient has died after receiving the high dose of Neurogene’s Rett syndrome gene therapy candidate. The biotech previously reported that the patient was in critical condition. |
|
Thursday, December 5, 2024 | 1pm ET / 10am PT Learn how to leverage comprehensive patient journeys to improve targeting, understand unmet needs, and optimize your competitive strategy with real-world evidence that sees what others can’t. Register now to gain a competitive edge by evolving beyond traditional, limited datasets and unlock a deeper understanding of patient and physician decision-making.
|
|
By Ayla Ellison,Andrea Park,Gabrielle Masson This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
By Darren Incorvaia,Zoey Becker Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own Chris Boshoff, M.D., Ph.D., for the job and prompting a domino effect of leadership changes. |
By Fraiser Kansteiner Pfizer has been tapped by Shanghai-based Zai Lab to help market the company’s antibacterial drug Xacduro in mainland China. The companies did not disclose the financial terms of the deal, which is slated to run through November 2028. The team-up comes as other drugmakers, like Merck, J&J and AstraZeneca, face challenges in the country. |
By Gabrielle Masson After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for chapter 11 bankruptcy. |
By Andrea Park New York-based health comms agency Calcium+Company is living up to its name, strengthening the bones of its business with the creation of a new division. |
By Kevin Dunleavy While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the United States, its baby power problems are only just beginning in the U.K. A British law firm representing 1,900 talc claimants has sent a letter to J&J, giving advance notice of a group-action lawsuit that it plans to file in the High Court in London, according to reports. |
By Darren Incorvaia Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. Louis have engineered an oral probiotic yeast to do the work for them, with the fungal cells able to release immune checkpoint inhibitors that shrank intestinal tumors in mice with colorectal cancer. |
By Kevin Dunleavy Interim results from a late-stage trial of Roche's Vabysmo on Asian patients with polypoidal choroidal vasculopathy suggest that the injected treatment is effective. After 16 weeks, patients showed vision improvement which was equivalent to reading roughly one and a half more lines on an eye chart. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now!
|
|
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
